• CDX is also a tumor suppressor gene

  2022-05-11

  

  CDX1 is also a tumor suppressor gene; the ablation of CDX1 and CDX2 results in a significant increase in tumor formation in the colon. CDX1 is regulated by epigenetic modification; the hypermethylation of the CpG island at the promoter is positively associated with severe clinical phenotypes. In add

• It has been suggested that MAPK Huang et al Uddman

  2022-05-11

  

  It has been suggested that MAPK (Huang et al., 2013, Uddman et al., 2003, Xu et al., 2008) signaling pathway is involved in the transcriptional upregulation of ETB receptor. The present study demonstrated that treatment with CsA increased phosphorylation of ERK1/2 and p38. Inhibition of ERK1/2 and p

• The lower number of samples tested

  2022-05-11

  

  The lower number of samples tested for the comparison between cobas 4800 HIV-1 and RealTime HIV-1, especially at or below 50 copies/mL (Table 6), could limit our ability to discern a difference in the ability of the various assays to identify patients with virological failure. However, the 95% CI ar

• To promote biomimetic growth of HAp Li et al developed

  2022-05-10

  

  To promote biomimetic growth of HAp, Li et al. [20] developed a technique to modify cellulose nanofibers using P2O5. It was ascertained that the negative phosphate groups bonded with Ca2+ through coordination bonds and subsequently guided the growth of the Ca–P crystals throughout the scaffolds. Sim

• Therefore we believe that HIF mediated effects on CSC

  2022-05-10

  

  Therefore, we believe that HIF-mediated effects on CSC markers, apoptosis are mediated through HO-1. Our plan is to look for more mechanistic studies to understand the role of HO-1 degradation products (CO, Fe, and bilirubin) in cellular apoptosis, stemness under hypoxia. The model of role of HO-1 i

• br Conclusion Infections caused by the P aeruginosa could

  2022-05-10

  

  Conclusion Infections caused by the P. aeruginosa could not be cured by current antibiotics, making multiple drug resistance of P. aeruginosa an increasing threat for human lives. Looking for a new therapeutic mechanism for infections caused by the P. aeruginosa has become a central issue. There

• br Authors contribution br Funding

  2022-05-10

  

  Authors' contribution Funding sources This study was supported by CDC intramural funding. Publication costs are funded by an internal program of CDC. MAT was supported by funds from the Association of Public Health Laboratories and CDC (APHL–CDC) Bioinformatics Fellowship Program. Competing

• br Brief overview of GSK inhibitors We

  2022-05-10

  

  Brief overview of GSK-3 inhibitors We will briefly summarize some of the key aspects about GSK-3 inhibitors. Additional details of GSK-3 inhibitors in clinical trials have been recently reviewed [5]. GSK-3 is a complicated target as it is involved in many biological processes from neurology, diab

• br Acknowledgements br Introduction Type

  2022-05-10

  

  Acknowledgements Introduction Type 2 diabetes is a progressive metabolic disorder which is characterised by chronic hyperglycaemia due to relative insulin deficiency, insulin resistance and increased hepatic glucose production [1]. The metabolism of glucose by glycolysis increases the ATP:ADP

• A few research articles described that PLGA could alone

  2022-05-10

  

  A few research articles described that PLGA could alone improve physiological activities in certain illnesses by exerting therapeutic effects. These reported therapeutic activities of PLGA can be appended to the hydrolysis products of PLGA lactate, glycolate, and H+. We will recapitulate their respe

• It has been proposed that

  2022-05-10

  

  It has been proposed that HCA1 may be a better target than HCA2 to treat dyslipidemia and to prevent progression of atherosclerosis, because HCA1 is less widely expressed, and HCA1 activation does not result in flushing. However, since the antilipolytic effects mediated by HCA2 appear to be not the

• br Results and discussion br Conclusions In summary we

  2022-05-10

  

  Results and discussion Conclusions In summary, we generated analogues of the hit compounds 1–3, studied their structure–activity relationships, and created a series of highly potent GPR55 agonists. The most potent agonists among the series were 17a-b, 17e, 17g and 17l with EC50 values below 10

• Recently we suggested that KYNA an endogenous GPR

  2022-05-10

  

  Recently, we suggested that KYNA – an endogenous GPR35 agonist could be produced in a human cornea since we showed the presence of the enzymes that catalyze the synthesis of KYNA – kynurenine aminotransferases I-III in corneal epithelium, stroma and endothelium (). Therefore, these findings provided

• br Experimental br Acknowledgments This research was

  2022-05-10

  

  Experimental Acknowledgments This research was supported by the Korea Research Foundation (2013R1A1A2007509). The authors thank to Dr. Moon Ho Son (Dong-A Pharm. Co. Ltd) for hGPR119 agonist activity assay. We also thank to Pharmacal Research Institute and Central Laboratory of Kangwon Nationa

• br Author contributions br Acknowledgements The

  2022-05-10

  

  Author contributions Acknowledgements The work was financially supported by a grant from the Investigator-Initiated Studies Program (Ref. #38124) from Merck Sharp & Dohme, and, in part, from Research Grants Council of the Hong Kong Special Administrative Region, China (Ref. No.: 14110314), awa

15729 records 420/1049 page Previous Next First page 上5页 416417418419420 下5页 Last page